Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 41.94 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 47.83 | Oscillator | Neutral |
| Williams %R (14) | -48.49 | Oscillator | Neutral |
| MACD (12, 26, 9) | -1.68 (Hist 0.33) | Oscillator | Buy |
| Average Directional Index (14) | 31.94 (+DI 18.4 / -DI 25.5) | Trend | Strong Sell |
| EMA 20 | 56.99 | MA | Sell |
| SMA 20 | 56.41 | MA | Sell |
| EMA 50 | 59.39 | MA | Strong Sell |
| SMA 50 | 61.71 | MA | Strong Sell |
| SMA 200 | 58.46 | MA | Strong Sell |
Current price $55.95
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 21, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 20, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Oct 20, 26 | JP Morgan | maintain | Overweight | Overweight |
| Oct 14, 26 | Barclays | maintain | Overweight | Overweight |
| Sep 10, 26 | HC Wainwright & Co. | maintain | Neutral | Neutral |
| Sep 1, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Aug 31, 26 | HC Wainwright & Co. | maintain | Neutral | Neutral |
| Aug 31, 26 | Jefferies | maintain | Buy | Buy |
| Aug 19, 26 | BMO Capital | maintain | Outperform | Outperform |
TTM vs. 5-year historical average (annual ratios)
| Metric | BMRN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 147.2x | 10.8x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 15.8x | EPS est. 3.53 | Discount |
| Price / Book | 1.7x | 3.1x | Discount |
| Price / Sales | 3.2x | 6.7x | Discount |
| EV / EBITDA | 36.7x | 104.5x | Discount |
| Return on equity | 1.2% | — | Weak |
| Gross margin | 75.5% | 77.1% | In line |
| Debt / Equity | 0.66 | 0.19 | Moderate |
| Piotroski / Altman Z | 4/9 | Z 1.83 | Grey zone |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2020 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 6, 2026 | 2026-10-06 16:22:54 | View |
| 4 | Oct 1, 2026 | 2026-10-01 16:23:08 | View |
| 8-K | Sep 30, 2026 | 2026-09-30 16:15:40 | View |
| 8-K | Sep 15, 2026 | 2026-09-15 08:31:45 | View |
| 4 | Sep 14, 2026 | 2026-09-14 18:55:01 | View |
| 3 | Sep 14, 2026 | 2026-09-14 18:48:31 | View |
| 8-K | Sep 14, 2026 | 2026-09-14 09:26:20 | View |
| 4 | Sep 3, 2026 | 2026-09-03 18:41:11 | View |
| 8-K | Sep 1, 2026 | 2026-09-01 09:23:17 | View |
| 8-K | Aug 31, 2026 | 2026-08-31 06:01:33 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,560 shares of the biotechnology company's stock after selling 422,526 shares during
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia.
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 0.95 | 1.20 | Beat 26.7% | $989.7M |
| May 4, 2026 | 0.78 | 0.76 | Miss -2.6% | $766.0M |
| Feb 23, 2026 | 0.17 | -0.24 | Miss -241.7% | $874.6M |
| Oct 27, 2025 | -0.15 | -0.16 | Miss -6.7% | $776.1M |
| Aug 4, 2025 | 0.86 | 1.23 | Beat 42.9% | $825.0M |
| May 1, 2025 | 0.71 | 0.97 | Beat 35.9% | $745.1M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Friberg Gregory R | officer: EVP, Chief R&D Officer | F-InKind | 4,086 @ $60.00 | $245.2K |
| Sep 10, 26 |
| Plenge Robert M |
| director |
| A-Award |
| 6,140 |
| — |
| Sep 10, 26 | Plenge Robert M | director: | 0 | — |
| Sep 2, 26 | Davis George Eric | officer: EVP, Chief Legal Officer | S-Sale | 17,557 @ $66.28 | $1.16M |
| Jun 2, 26 | Countouriotis Athena | director | A-Award | 7,490 | — |
| Jun 2, 26 | Walbert Timothy P | director | A-Award | 7,490 | — |
| Jun 2, 26 | Ho Maykin | director | A-Award | 7,490 | — |
| Jun 2, 26 | Hombach Robert J. | director | A-Award | 7,490 | — |